Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- News pre|CISION Platform: Delivering Two Complementary Therapies from One Molecule October 27, 2025
- Helicon Degraders Show a New Path in Prostate Cancer Therapy October 27, 2025
- UPDATE 2: HLD-0915 Shows Promising Early Results in Drug-Resistant Prostate Cancer October 27, 2025
- Newsletter 43/2025 October 26, 2025
Follow-up of ARCHES Trial Shows Extended Survival
/in Clinical Trial, Metastatic, Phase 3/by MaxIND Required for ITC-6146RO for Solid Tumors Overexpressing the B7-H3 Protein
/in Clinical Trial, Metastatic, Phase 1/by MaxOn August 29, 2025, a clinical trial plan (Investigational New Drug application) was submitted to the Ministry of Food and Drug Safety (MFDS) of South Korea to initiate phase 1 clinical trials for ITC-6146RO. ITC-6146RO is an antibody-drug conjugate (ADC) designed to target solid tumors overexpressing the B7-H3 protein, such as metastatic castration-resistant prostate cancer […]
Anti-PD-L1 Therapy Shows Promise for MMR-Deficient Metastatic Prostate Cancer
/in Clinical Trial, Metastatic/by MaxPhase 2 Trial: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response via Modulation of Androgen Receptor (SPIDERMAN)
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 1: AMG 509 (Xaluritamig) for Metastatic Hormone Sensitive Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1: Lartesertib and Tuvusertib Target DNA Repair to Fight Resistant Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxDecipher Test Emerges as Key Predictor for Chemotherapy Benefit in Metastatic Prostate Cancer
/in Retrospective studies/by MaxThe Promise of In Vivo CAR T Cell Therapies
/in Not PCa related/by Max